BioInvent International AB (STU:BIX) Net Change in Cash : €1.02 Mil (TTM As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

BioInvent International AB's Net Change in Cash for the three months ended in Mar. 2025 was €3.07 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was €1.02 Mil.

BioInvent International AB Net Change in Cash Historical Data

The historical data trend for BioInvent International AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Net Change in Cash Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

56.55

17.67

-36.07

-23.14

15.25

BioInvent International AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															17.88	-0.43	22.01	-23.63	3.07

BioInvent International AB Net Change in Cash Calculation

BioInvent International AB's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-33.812	+	49.062	+	0	+	0
	=	15.25

BioInvent International AB's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -10.954 + 14.228 + -0.203 + 0

= 3.07

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of BioInvent International AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Net Change in Cash

Comparable Companies

OSTO:HNSA OSTO:VICO OSTO:GENO OSTO:EGTX OSTO:XSPRAY OSTO:SANION OSTO:SYNACT OSTO:DMYD B XSAT:HAMLET B OSTO:IBT B VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270

Traded in Other Exchanges

BINV:Sweden 0H22:UK BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines